Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Pharma
Pfizer's Ibrance scores in double-positive breast cancer
Looking beyond HR+/HER2- breast cancer, Pfizer has found a unique opportunity for Ibrance in HR+/HER2+ tumors.
Angus Liu
Dec 12, 2024 8:15am
ASH: Lilly defends survival data blemish in novel BTK trial win
Dec 9, 2024 5:45pm
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
ASH: GSK details Blenrep's survival win against J&J's Darzalex
Dec 9, 2024 1:30pm
Keytruda-Lynparza combo scores tepid win in ovarian cancer trial
Dec 9, 2024 11:18am
ASH: AstraZeneca proposes fixed-duration Calquence combos in CLL
Dec 8, 2024 11:00am
